Cancer: Medical Treatments
The question
To ask the Secretary of State for Health and Social Care, how many myeloma patients are receiving a fourth line treatment; and what proportion of those patients are being treated with isatuximab in combination with pomalidomide and dexamethasone.
Answered by Karin Smyth
Information on the number of myeloma patients receiving a fourth line treatment is not held centrally. However, the following table shows the number of patients notified to receive isatuximab, in combination with pomalidomide and dexamethasone, in 2021, 2022, 2023 and from January to July of 2024:
| 2021 | 2022 | 2023 | 2024 |
Patients notified to receive isatuximab, pomalidomide, and dexamethasone | 508 | 522 | 464 | 278 |
Source: NHS England.
Note: not all patients will necessarily go on to receive the treatment itself.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →